Owing to overexpressing of some proteins, for example epidermal growth factor receptor (EGFR), in cancer cells with drug resistance, specific monoclonal antibody-modified nanoparticles can be used to overcome EGFR resistance cancer. This evidence concerns the gene EGFR and cancer.